Press Releases

Press releases 2020

June 4, 2020
Quest Provides Corporate Update

May 29, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings

May 1, 2020
Quest PharmaTech Announces Results from its April 28, 2020 AGM

April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

March 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer

March 13, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.

Press releases 2019

September 25, 2019
OncoQuest Receives “Notice of Allowance” for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients

January 29, 2019
Quest PharmaTech Announces Results from AGM

January 25, 2019
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

Press releases 2018

December 19, 2018
Quest PharmaTech Adopts Amendment to By-laws Requiring Advance Notice of Nomination of Directors

December 3, 2018
Quest PharmaTech Announces Adoption of Shareholder Rights Plan

November 28, 2018
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.

Jul 20, 2018
Madenco Biosciences Announces Strategic Decision to Drop Consumer Health Products and Focus on Pharmaceutical Product Development

Jun 1, 2018
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting

May 14, 2018
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer

February 12, 2018
OncoQuest to Present at BIO CEO & Investor Conference

February 6, 2018
OncoQuest Completes US $6 Million Private Placement

January 3, 2018
Madenco Biosciences Announces Licensing Agreement for Patented EGF Wound Healing Technology

Press releases 2017

November 14, 2017
OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)

November 7, 2017
OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017

November 6, 2017
Quest PharmaTech Announces Results from its November 2017 AGM

October 26, 2017
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting

August 28, 2017
Quest PharmaTech Receives $1,666,667 of Funding Proceeds Through Exercise of Warrants

July 19, 2017
Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors

May 24, 2017
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2017
Madenco Biosciences Creates New Line of Cosmeceuticals to Complement Bellus Skin™ Serum for Anti-Aging

May 9, 2017
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

May 4, 2017
Quest PharmaTech Expands Its Consumer Health Product Pipeline with Clinically Validated Natural Allergy Relief

February 15, 2017
Quest PharmaTech Announces Results from its 2017 AGM

Press releases 2016

December 7, 2016
OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

November 29, 2016
OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

November 14, 2016
Bellus Skin Rejuvenation Serum: Quest PharmaTech Launches Scientifically Proven, Clinically Validated Premium Skin Care Cosmetics in Canada

November 2, 2016
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

October 28, 2016
Quest PharmaTech Inc. Announces Change of Auditor

October 20, 2016
Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

September 16, 2016
Quest PharmaTech Inc. Amends Warrant Terms

September 6, 2016
Quest PharmaTech Inc. Retains Haft Group for Financial Services

August 5, 2016
Quest PharmaTech Announces Filing of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016

Mar 22, 2016
Quest PharmaTech’s Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

Press releases 2015

Dec 10, 2015
Quest PharmaTech Receives U.S. $2 Million for its ImmunoPhotodynamic Therapy Assets

Dec 1, 2015
Quest PharmaTech Announces Results from its 2015 AGM

Nov 18, 2015
Quest PharmaTech’s Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

Oct 13, 2015
Quest PharmaTech Closes $2,000,000 Private Placement With Hepalink USA

Jul 27, 2015
Quest PharmaTech Closes $1,000,000 Private Placement

Jan 13, 2015
Quest PharmaTech Announces Funding Support from National Research Council’s Industrial Research Assistance Program for IgE Antibody Cancer Immunotherapy Development (AllergoOncology)

Press release 2014

Nov 10, 2014
Quest PharmaTech Announces Results from its 2014 AGM

Oct 22, 2014
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin; Dr. Jacqueline Shan, Creator of COLD FX;, to Assist

Oct 2, 2014
Quest PharmaTech Signs License Agreement with Bioceltran Co., Ltd. for Photodynamic Therapy Technology

Sep 16, 2014
Quest PharmaTech Provides Financial Update

Jun 9, 2014
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer

Jan 29, 2014
Quest PharmaTech Announces Third Combinatorial Immunotherapy Clinical Trial for Oregovomab with a TLR3 agonist, Hiltonol®

Press release 2013

Nov 21, 2013
Quest PharmaTech Announces $1,000,000 Non-Brokered Private Placement

Nov 7, 2013
Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to present late-breaking data at the 28th Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8 – 10, 2013 in Maryland, U.S.

Jul 23, 2013
Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer

Apr 8, 2013
Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti – PSA IgE Technology; UCLA researchers to present anti – PSA IgE preclinical data at the 2013 American Association for Cancer Research Conference

Jan 22, 2013
Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

Press releases 2012

Oct 2, 2012
Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer

Jul 31, 2012
Quest PharmaTech Announces Results from its 2012 AGM